-
Bevifibatide Citrate Injection Approved for Marketing by China NMPA
2025-02-19
Recently, the he Category 1 innovative drug Bevifibatide Citrate Injection (trade name: 贝塔宁/BETAGRIN) of Bio-Thera Solutions, Ltd. is approved for marketing by China NMPA.
-
Fultagliptin Benzoate Tablets Approved for Marketing by China NMPA
2025-02-19
Recently, the Category 1 innovative drug Fultagliptin Benzoate Tablets (trade name: 信立汀) of Shenzhen Salubris Pharmaceuticals Co., Ltd. is approved by China NMPA.
-
Fulzerasib Tablets Approved with Conditions for Marketing by China NMPA
2025-02-19
Recently, the Category 1 innovative drug Fulzerasib Tablets (trade name:达伯特) of Innovent Biologics, Inc. is approved with condition for marketing through the priority review and approval procedure by China NMPA.
-
Tendvia™ Pulmonary Artery Thrombectomy System Approved for Marketing
2025-02-19
Recently, the innovative product Tendvia™ Pulmonary Artery Thrombectomy System of Shanghai Tendfo Medical Device Co., Ltd. is approved by China NMPA.
-
Transjugular Intrahepatic Puncture Device Approved for Marketing
2025-02-19
Recently, the innovative product "transjugular intrahepatic puncture device" of Beijing Ailin Medical Technology Co., Ltd. is approved for marketing by China NMPA.
-
Disposable Radiofrequency Atrial Septal Puncture Needle Approved for Marketing
2025-02-19
Recently, the innovative product Disposable Radiofrequency Atrial Septal Puncture Needle of Hangzhou Nuosheng Medical Technology Co., Ltd. is approved for marketing by China NMPA.
